The DOI matches its Crossref record.
Efficacy of Bacteriophage Therapy against Gut-Derived Sepsis Caused by Pseudomonas aeruginosa in Mice
Open accessAbstract
We evaluated the efficacy of bacteriophage (phage) therapy by using a murine model of gut-derived sepsis caused by Pseudomonas aeruginosa that closely resembles the clinical pathophysiology of septicemia in humans. Oral administration of a newly isolated lytic phage strain (KPP10) significantly protected mice against mortality (survival rates, 66.7% for the phage-treated group versus 0% for the saline-treated control group; P < 0.01). Mice treated with phage also had lower numbers of viable P. aeruginosa cells in their blood, liver, and spleen. The levels of inflammatory cytokines (tumor necrosis factor alpha TNF-α, interleukin-1β [IL-1β], and IL-6) in blood and liver were significantly lower in phage-treated mice than in phage-untreated mice. The number of viable P. aeruginosa cells in fecal matter in the gastrointestinal tract was significantly lower in phage-treated mice than in the saline-treated control mice. We also studied the efficacy of phage treatment for intraperitoneal infection caused by P. aeruginosa and found that phage treatment significantly improved the survival of mice, but only under limited experimental conditions. In conclusion, our findings suggest that oral administration of phage may be effective against gut-derived sepsis caused by P. aeruginosa .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria
Kortright, K. E., Chan, B. K., Koff, J. L., & Turner, P. E. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.01.014 · Cited by 1,212
Phage therapy: An alternative to antibiotics in the age of multi-drug resistance
Lin, D. M., Koskella, B., & Lin, H. C. (2017) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v8.i3.162 · Cited by 1,135
Wittebole, X., De Roock, S., & Opal, S. M. (2014) · Virulence · doi:10.4161/viru.25991 · Cited by 599
Formulation, stabilisation and encapsulation of bacteriophage for phage therapy
Malik, D. J., Sokolov, I. J., Vinner, G. K., Mancuso, F., Cinquerrui, S., Vladisavljevic, G. T., Clokie, M. R. J., Garton, N. J., Stapley, A. G. F., & Kirpichnikova, A. (2017) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2017.05.014 · Cited by 594
Cullin, N., Azevedo Antunes, C., Straussman, R., Stein-Thoeringer, C. K., & Elinav, E. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.006 · Cited by 578
“, 2012) featured preliminary effectiveness against bacterial infections in mice (Nale et al., 2016;Watanabe et al., 2007) and humanpatients (Petrovic Fabijan et al.”
BackgroundFederici, S., Kredo-Russo, S., Valdés-Mas, R., Kviatcovsky, D., Weinstock, E., Matiuhin, Y., Silberberg, Y., Atarashi, K., Furuichi, M., Oka, A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.07.003 · Cited by 542
Merabishvili, M., Pirnay, J.-P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., Glonti, T., Krylov, V., Mast, J., Van Parys, L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004944 · Cited by 511
Hwang, I. Y., Koh, E., Wong, A., March, J. C., Bentley, W. E., Lee, Y. S., & Chang, M. W. (2017) · Nature Communications · doi:10.1038/ncomms15028 · Cited by 472
Dąbrowska, K. (2019) · Medicinal Research Reviews · doi:10.1002/med.21572 · Cited by 375
The factors affecting effectiveness of treatment in phages therapy
Ly-Chatain, M. H. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00051 · Cited by 331
Bacteriophages Can Treat and Prevent Pseudomonas aeruginosa Lung Infections
Debarbieux, L., Leduc, D., Maura, D., Morello, E., Criscuolo, A., Grossi, O., Balloy, V., & Touqui, L. (2010) · The Journal of Infectious Diseases · doi:10.1086/651135 · Cited by 304
Halawa, E. M., Fadel, M., Al-Rabia, M. W., Behairy, A., Nouh, N. A., Abdo, M., Olga, R., Fericean, L., Atwa, A. M., El-Nablaway, M., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1305294 · Cited by 280
A Method for Generation Phage Cocktail with Great Therapeutic Potential
Gu, J., Liu, X., Li, Y., Han, W., Lei, L., Yang, Y., Zhao, H., Gao, Y., Song, J., Lu, R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031698 · Cited by 268
Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review
Kakasis, A., & Panitsa, G. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.09.004 · Cited by 261
Phages and their potential to modulate the microbiome and immunity
Federici, S., Nobs, S. P., & Elinav, E. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00532-4 · Cited by 222
Metadata
- Authors
- Watanabe, R., Matsumoto, T., Sano, G., Ishii, Y., Tateda, K., Sumiyama, Y., Uchiyama, J., Sakurai, S., Matsuzaki, S., Imai, S., & Yamaguchi, K.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2007-02
- Volume
- 51
- Issue
- 2
- Pages
- 446-452
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2151390091
- Cited by
- 206
- References
- 0
- FWCI
- 5.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.